Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study

Autor: Alex Assuied, Izabella Zarea, Loïc Coutte, Ken Solovay, Jann Storsaeter, Delphine Jean, Keith Rubin, Åsa Linde, Claire Bauduin, Sonia Gueguen, Nina Ekholm, Dominique Raze, Teghesti Tecleab, Erla Sigurdardottir, Noémie Mercier, Laetitia Moinot, Margaretha Ljungman, Margareta Gustafsson, Florence Allais, Cecilia Lång, Nathalie Mielcarek, Gabrielle Derocle, Eva Hanson Pihlainen, Inga-Lill Reinholdsson, Marcel Thalen, Cédrick Wallet, Camille Locht, Philippe Reboud, Nabil Al-Tawil, Geneviève Chêne, Hélène Espérou, Alpha Diallo, Maja Jahnmatz, Ludivine Taïeb, Emilie Rousseau, Teodora Aktas, Fabien Le Marec, Camille Gilbert, Ingrid Andersson, Céline Colin, Céline Roy, Christine Schwimmer, Maria Nastase, Lena Dager, Maj Ringman, Rigmor Thorstensson, Anne-Sophie Debrie, Lena Wehlin, Anneli Wahlberg, Claire Lévy-Marchal, Laura Richert

Publikováno v: The Lancet Infectious Diseases
The Lancet Infectious Diseases, 2020, ⟨10.1016/s1473-3099(20)30274-7⟩
The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2020, ⟨10.1016/s1473-3099(20)30274-7⟩

Summary Background Long-term protection and herd immunity induced by existing pertussis vaccines are imperfect, and a need therefore exists to develop new pertussis vaccines. This study aimed to investigate the safety, colonisation, and immunogenicit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a47cf071894c2c14229d531ae89de4c8
https://www.hal.inserm.fr/inserm-02904617/file/S1473309920302747.pdf